Healthpeak: Leaning Into the Life Science Inflection and Scaling Senior Housing
A strategic capital recycling deal and a raised guidance paint a picture of a REIT ready to deploy after four years of patience.
PEAK · Earnings Call · 2026-08-05
A Pivot From Defensive to Offensive
For the first time in four years, Scott Brinker, CEO of Healthpeak Properties, sounds like a buyer, not a caretaker. On the Q2 2026 call, he opened with a tribute to the team's "winning mindset" during the downturn, then pivoted to what comes next: “As the life science pendulum finally starts to swing back in our favor…” — Scott Brinker, Executive · 2026-08-05 The company is now using its balance sheet to grow, having closed a $1 billion outpatient medical recapitalization with Brookfield and an earlier JV with Blackstone. That is not just capital recycling; it is a strategic move to position Healthpeak as the preferred operating partner in a sector many investors had written off.
Life Science: Occupancy Gains and a New Playbook
The lab portfolio is showing real momentum. Kelvin Moses, CFO, reported total occupancy for the Lab segment rose 80 bps sequentially to 78.5%, a 140 bps improvement since year-end 2025. Leasing volume remains healthy—381,000 square feet executed in the quarter, with 480,000 under LOI. The Torrey Pines story is especially telling: leased percentage in that submarket jumped from ~65% to 97% when including LOIs. This is not merely a cyclical bounce; it reflects a structural shift in how Healthpeak is being viewed. As Scott Bohn noted, the company is seeing more deals in the 25,000-75,000 SF range, a sign that venture funding is trickling back into biotech.
The company is also signaling a new acquisition appetite. Scott Brinker said the next few years will be "an acquisition game" rather than a development game. Healthpeak is already working on multiple distressed or undervalued lab opportunities, including the Gateway asset acquired earlier. The strategy is to partner with lenders and use its platform to lease up buildings that others cannot.
We're working on a number of situations… I think we'll end up being a consolidator over the next 24 months, which should prove to be a great time to grow the portfolio.
This is a marked shift from the past two years when the company was more defensive and focused on renewals and maintaining occupancy.
Capital Recycling and a Fortress Balance Sheet
The Brookfield transaction is a centerpiece of the quarter. Healthpeak retains a 51% interest in a 5.6 million square foot outpatient portfolio while raising $1 billion of cash. The deal generates a 5.9% trailing cash cap rate, and after seven years, Healthpeak has call rights to repurchase the noncontrolling interest at a 6.5% unlevered return. This is creative structuring, and it gives the company capital to pursue opportunities across all three segments. Scott Brinker emphasized the balance sheet: “Our balance sheet is stronger than it's ever been. Leverage is below 5x, and we have flexibility to pursue a number of capital allocation alternatives.” — Scott Brinker, Executive · 2026-08-05 The company also raised its FFO guidance by $0.02 to $1.73-$1.77, citing a 75 bps same-store NOI increase and the repayment of a $400 million seller note. This is the kind of earnings growth that drives re-rating.
The debt maturity wall is being managed. Healthpeak repaid $900 million of debt through August 4, including $650 million of senior unsecured notes, and has $4.1 billion of liquidity. The company has also been opportunistic on buybacks, repurchasing $100 million of stock at a 10%+ FFO yield. But with leverage below its 5.5x target, the message is patience. "This is not the right environment to have elevated leverage," Brinker noted, pointing to cap rates versus borrowing costs.
Senior Housing: Doubling Down
The Janus Living platform is exceeding expectations. In Q2, Janus delivered 19% NOI growth on a same-store basis, with occupancy up 260 bps. Healthpeak's stake is now 74%, representing ~$6.5 billion of equity value. The company has closed $1.8 billion of senior housing acquisitions since January, and the portfolio is on pace to double in size this year. Brinker called it a "3-year business plan in 12 months." This expansion is funded through a combination of JVs and the company's own balance sheet, again leveraging relationships rather than paying retail prices.
What Changed, and Why It Matters
The key shift is the company's confidence. After years of managing through a lab downturn, Healthpeak is now seeing the life sciences sector stabilize, and it is aggressively positioning itself to be a consolidator. The outpatient medical business has become a reliable cash generator, and senior housing is scaling quickly. The company's commercial readiness is evident in the Brookfield and Blackstone partnerships—both global investors chose Healthpeak as their operating partner, a testament to its platform. With a fortified balance sheet, Healthpeak is finally in a position to do what great investors do: act when others are hesitant.
This is an earnings call that tells a transformed story. The numbers are improving, but more importantly, the tone is forward-looking. The company is not just talking about occupancy; it is talking about acquisitions, partnerships, and scale. For investors who have waited through the life science downturn, this is the first real sign that Healthpeak is emerging as a winner.